Health‐related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease

Abstract

The main objective of this study was to compare health-related quality of life (HRQOL) of primary immune thrombocytopenia (pITP) patients with that of general population, overall, and by patient group (i.e., newly diagnosed, persistent, and chronic patients). Fatigue was also investigated as a secondary objective. Overall, 424 adult patients were enrolled in a multicenter observational study and the control group consisted of a representative sample from the general population. Propensity score matching plus further multivariate linear regression adjustment was used to compare HRQOL outcomes between pITP patients and general population. Mean age of patients was 54 years. Of those with HRQOL assessment, 99 patients (23.6%) were newly diagnosed, 53 (12.6%) were persistent, and 268 (63.8%) were chronic pITP patients. Comparison by patient group versus their respective peers in the general population revealed greater impairments in persistent pITP patients. Persistent pITP patients reported clinically meaningful impairments in physical functioning (-15; 95% CI -24.1 to -5.8; P = 0.002), social functioning (-15.3; 95% CI -25.5 to -5.1; P = 0.004), role physical (-28.4; 95% CI -43.1 to -13.7; P < 0.001), role emotional (-23.9; 95% CI -40.1 to -7.7; P = 0.004), and mental health scales (-11.3; 95% CI -21.2 to -1.4; P = 0.026) of the SF-36 questionnaire. Higher fatigue severity was associated with lower physical and mental HRQOL outcomes. Our findings suggest that the burden of the disease and treatment might depend on the disease phase and that persistent pITP patients are the most vulnerable subgroup. Am. J. Hematol. 91:995-1001, 2016. © 2016 Wiley Periodicals, Inc.

Patterns and influences in health‐related quality of life in children with immune thrombocytopenia: A study from the Dallas ITP Cohort

“…Persistence of disease has also been noted to impact HRQoL in a recent prospective cohort study of Dutch children with newly diagnosed ITP . Parent and/or patient anxiety as well as fatigue or restrictions on daily activities may factor into this finding …”

“…10 Parent and/or patient anxiety as well as fatigue or restrictions on daily activities may factor into this finding. 10,17 Though treatment in children with newly diagnosed ITP has not been shown to improve HRQoL, 7,10 it may lessen parent disease burden in children with persistent/chronic ITP. Klaassen et al 5…”

A prospective, multicenter study of low dose decitabine in adult patients with refractory immune thrombocytopenia

“…HRQoL is an important tool to evaluate the influence of disease and the therapeutic efficacy of treatment. 35,36 In this study, HRQoL was assessed based on ITP-PAQ, including ITP-related symptoms, fatigue, activity, psychological health, fear, overall quality of life, social activity, and work. 24 Note, ITP-PAQ was shown to have fairly good responsiveness, reliability, and validity.…”

Eltrombopag, low‐dose rituximab, and dexamethasone combination as frontline treatment of newly diagnosed immune thrombocytopaenia

“…The capacity of eltrombopag and rituximab for improving T cell subsets, particularly Tregs, may help explain these observations (Bao et al , ). This strategy could lead to cost‐efficiency, with a total cost of US$1400 in our institution, compared with that of continued treatment and loss of work productivity, issues relevant in a limited‐resources context (Efficace et al , ).…”